This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
U.S. Food and Drug Administration Table of Pharmacogenomic Biomarkers in Drug Labels. USDA: Silver Spring, MD. Available at: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
Obama B (2015). Remarks by the President on Precision Medicine. Office of the Press Secretary. January 30, 2015. Available at: https://www.whitehouse.gov/the-press-office/2015/01/30/remarks-president-precision-medicine (accessed 10/2016).
Meckley LM, Neumann PJ . Personalized medicine: factors influencing reimbursement. Health Policy 2010; 94: 91–100.
Bielinski SJ, Olson JE, Pathak J, Weinshilboum RM, Wang L, Lyke KJ et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc 2014; 89: 25–33.
Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther 2014; 96: 482–489.
Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012; 92: 87–95.
Power of One Million. Blog.23andme.com/news/one-in-a-million. Available at https://www.23andme.com/?utm_source=bing&utm_medium=cpc&utm_campaign=Search-Branded&utm_content=23c_Search_Paid_Brand&dclid=CJrx9MmY088CFUspaQodMxAENw (accessed 10/2016).
Szanton SL, Allen JK, Thorpe RJ Jr, Seeman T, Bandeen-Roche K, Fried LP . Effect of financial strain on mortality in community-dwelling older women. J Gerontol B Psychol Sci Soc Sci 2008; 63: S369–S374.
Wedlund PJ, de Leon J . Pharmacogenomic testing: the cost factor. Pharmacogenomics J 2001; 1: 171–174.
Wong WB, Carlson JJ, Thariani R, Veenstra DL . Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 2010; 28: 1001–1013.
Monaco AD, Beretta M, Pugliese S, Valente D, Francia RD . Early outline evaluation of genotyping costs of pharmacogenomics. J Pharmacogenomics Pharmacoproteomics 2014; 5: 123.
Brothers KB, Rothstein MA . Ethical, legal and social implications of incorporating personalized medicine into healthcare. Per Med 2015; 12: 43–51.
Hedgecoe A . The Politics of Personalised Medicine - Pharmacogenetics in the Clinic. Cambridge University Press: Cambridge, UK, 2005.
Tehranifar P, Neugut AI, Phelan JC, Link BG, Liao Y, Desai M et al. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Biomarkers Prev 2009; 18: 2701–2708.
Goldenberg AJ, Hartmann CD, Morello L, Brooks S, Colon-Zimmermann K, Marshall PA . Gene-environment interactions and health inequalities: views of underserved communities. J Community Genet 2013; 4: 425–434.
Rotimi C, Shriner D, Adeyemo A . Genome science and health disparities: a growing success story? Genome Med 2013; 5: 61.
Kahn J . How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine. Yale J Health Policy Law Ethics 2004; 4: 1–46.
Rothstein MA, Epps PG . Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2: 228–231.
Lee SS . Racializing drug design: implications of pharmacogenomics for health disparities. Am J Public Health 2005; 95: 2133–2138.
Frank R . What to make of it? The (Re)emergence of a biological conceptualization of race in health disparities research. Soc Sci Med 2007; 64: 1977–1983.
Acknowledgements
This work was supported in part by Mayo Clinic Center for Individualized Medicine, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, National Institutes of Health grants U19 GM61388 (The Pharmacogenomics Research Network), R01 GM28157, U01 HG005137, R01 CA138461, R01 AG034676 (The Rochester Epidemiology Project), U01 HG06379 and U01 HG06379 Supplement (The Electronic Medical Record and Genomics (eMERGE) Network).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Bielinski, S., St Sauver, J., Olson, J. et al. Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?. Pharmacogenomics J 17, 1–3 (2017). https://doi.org/10.1038/tpj.2016.72
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2016.72
This article is cited by
-
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation
BMC Cancer (2022)
-
Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis
Translational Psychiatry (2021)